Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ 1,316,520 $ 1,732,230 $ 4,564,602 $ 5,488,633
General and administrative 749,474 675,115 2,354,645 2,139,246
Total operating expenses 2,065,994 2,407,345 6,919,247 7,627,879
Loss from operations (2,065,994) (2,407,345) (6,919,247) (7,627,879)
Interest income 112,260 7,698 330,966 8,579
Net loss (1,953,734) (2,399,647) (6,588,281) (7,619,300)
Other comprehensive income (loss):        
Foreign currency translation gain (loss) 6,930 25,519 (8,254) 46,145
Unrealized gain (loss) on investments (10,203) 0 3,261
Comprehensive loss $ (1,957,007) $ (2,374,128) $ (6,593,274) $ (7,573,155)
Net loss per share:        
Basic and diluted (in dollars per share) $ (0.14) $ (0.19) $ (0.49) $ (0.6)
Weighted average shares outstanding:        
Basic and diluted (in shares) 14,118,397 12,754,685 13,551,776 12,664,387